Egashira et al., 2018 - Google Patents
Characterization of glycoengineered anti-HER2 monoclonal antibodies produced by using a silkworm–baculovirus expression systemEgashira et al., 2018
- Document ID
- 3149593079659219119
- Author
- Egashira Y
- Nagatoishi S
- Kiyoshi M
- Ishii-Watabe A
- Tsumoto K
- Publication year
- Publication venue
- The journal of biochemistry
External Links
Snippet
Silkworm–baculovirus expression systems are efficient means for the production of recombinant proteins that provide high expression levels and post-translational modifications. Here, we characterized the stability, glycosylation pattern and antibody …
- 108010045030 monoclonal antibodies 0 title abstract description 72
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goh et al. | Impact of host cell line choice on glycan profile | |
| Wada et al. | Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms | |
| Raymond et al. | Production of α2, 6-sialylated IgG1 in CHO cells | |
| Reusch et al. | Fc glycans of therapeutic antibodies as critical quality attributes | |
| Dekkers et al. | Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans | |
| Hamilton et al. | Production of sialylated O-linked glycans in Pichia pastoris | |
| Thomann et al. | In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity | |
| Shatz et al. | Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity | |
| Iizuka et al. | Production of a recombinant mouse monoclonal antibody in transgenic silkworm cocoons | |
| Yu et al. | Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans | |
| JP6750148B2 (en) | Process for producing sugar chain cleaving antibody and uniform sugar chain antibody | |
| Rose et al. | Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG | |
| Ha et al. | Biochemical and biophysical characterization of humanized IgG1 produced in Pichia pastoris | |
| Delobel | Glycosylation of therapeutic proteins: A critical quality attribute | |
| KR102232348B1 (en) | Cells producing fc containing molecules having altered glycosylation patterns and methods and use thereof | |
| Tada et al. | Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori) | |
| Palmberger et al. | Insect cells for antibody production: evaluation of an efficient alternative | |
| Liu et al. | Impact of IgG fc‐oligosaccharides on recombinant monoclonal antibody structure, stability, safety, and efficacy | |
| Popp et al. | Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function | |
| Cambay et al. | Impact of N-glycosylation on Fcγ receptor/IgG interactions: Unravelling differences with an enhanced surface plasmon resonance biosensor assay based on coiled-coil interactions | |
| Dorokhov et al. | Functional role of carbohydrate residues in human immunoglobulin G and therapeutic monoclonal antibodies | |
| Cosgrave et al. | N-linked glycan structures of the human Fcγ receptors produced in NS0 cells | |
| Egashira et al. | Characterization of glycoengineered anti-HER2 monoclonal antibodies produced by using a silkworm–baculovirus expression system | |
| Wang et al. | The interplay of protein engineering and glycoengineering to fine‐tune antibody glycosylation and its impact on effector functions | |
| Das et al. | Recombinant monoclonal antibody production in yeasts: challenges and considerations |